Work

Clinical Success of Complex Biological Therapies: Be Careful What You Wish For...

Year: 2010

Type: article

Abstract: Would-be gene and cell therapists have longed for the day when they could escape the sneer that their field was 5 years from success—and has been that way for 20 years. Fortunately, our wish has been granted, for an increasing number of reports of clinical success in genetic diseases and cancer are appearing in high-profile journals and are being widely acknowledged. But now that this first stage has passed, we are left with what is in many ways a more intractable problem. How do we ensure that safe and effective complex biological therapies (CBTs) become licensed products that are sufficiently viable from a commercial standpoint to be widely distributed as the standard of clinical practice? In a series of articles over the coming year, Molecular Therapy will examine these issues in more detail, but I will begin by outlining the problem here.

Source: Molecular Therapy

DOI: 10.1038/mt.2010.204

Author: Malcolm K Brenner

Institution: Houston Methodist

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500